Biocom California’s Regulatory Affairs Committee aims at addressing regulatory and scientific issues faced by the life science community of California. The committee provides insight on legislative and regulatory proposals affecting the industry, recommends official positions, and acts as a resource for the Biocom California membership.
Committee members are at the forefront of FDA’s and other agencies’ activities through regular updates by Biocom California staff on the latest legislative and regulatory developments. The Committee helps review and comment on select legislative proposals, rulemaking, and guidances affecting the industry.
The Committee helps review and comment on select legislative proposals, rulemaking, and guidances affecting the industry, and recommends positions to the Public Policy Oversight Committee, which is tasked with developing Biocom California’s official positions. The Committee also provides feedback on Biocom California events and initiatives related to regulatory activities.
In the past years, committee members have engaged in a broad range of issues, including FDA funding, user fees reauthorization negotiations, legislative proposals to improve the drug and device review and approval process, FDASIA implementation, the biosimilars approval pathway, and compounding regulations, among many others.
Meetings, featuring special programming, are held once a quarter. Committee members are strongly encouraged to attend to enjoy networking, exchanging best practices, and discussing regulatory matters of common interest.